Posted on August 22, 2014 by Sitemaster
The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, Diagnosis, radiation, risk, zoledronate, zoledronic | 6 Comments »
Posted on September 26, 2011 by Sitemaster
According to another study presented at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm this weekend, the bone-strengthening bisphosphonate ibandronate (Boniva®) seems to work just as well as radiotherapy for the management of pain associated with prostate cancer that has metastasized to the bones. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Boniva, ibandronate, pain, radiation therapy, skeletal-related event, SRE, zoledronate | Leave a comment »
Posted on June 5, 2010 by Sitemaster
Saturday was never going to be a major day for prostate cancer at the annual meeting of the American Society for Clinical Oncology (ASCO) here in Chicago. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Risk | Tagged: denosumab, skeletal-related events, zoledronate | Leave a comment »
Posted on April 20, 2010 by Sitemaster
In today’s news reports we note new articles dealing with:
- Biopsy protocols, patient selection, and focal therapy
- Tertiary Gleason pattern 4/5 and risk for progression post-RP
- Evolving data on the uses of bisphosphonates and denosumab
- SKIs in treatment of advanced forms of prostate cancer … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, dasatinib, denosumab, focal therapy, Gleason, saracatinib, tertiary, zoledronate | 7 Comments »
Posted on February 9, 2010 by Sitemaster
A media release issued yesterday by Amgen claims that denosumab “demonstrated superiority” over zoledronate (Zometa) in a randomized, multi-center, Phase III clinical trial in prostate cancer patients with bone metastases. … READ MORE …
Filed under: Drugs in development, Management | Tagged: bone loss, denosumab, SREs, zoledronate, Zometa | Leave a comment »
Posted on July 7, 2009 by Sitemaster
Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases. … READ MORE …
Filed under: Drugs in development | Tagged: denosumab, skeletal-related events, SREs, zoledronate | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 